Antibiotics Market to Reach USD 45.30 Billion in 2028; Rising Development of Novel Combination Therapies to Bolster Growth Globally

91

The global “antibiotics market” is set to gain impetus from the rising development of novel combination therapies by biopharmaceutical companies, mainly because of the surging awareness of antibiotic-resistant infections. Allecra Therapeutics GmbH, for instance, is currently developing cefepime/enmetazobactam for treating complex resistance issues. This information is given by Fortune Business Insights™ in a published report, titled, “Antibiotics Market, 2021-2028.” As per the report, the market size was USD 37.35 billion in 2020. It is projected to grow from USD 38.08 billion in 2021 to USD 45.30 billion in 2028 at a CAGR of 2.5% during 2021-2028.

Industry Developments-

  • May 2021: Sandoz announced its plan to expand production capabilities of antibiotics in Palafolls and Kundl. It aims to enhance its ability to provide premium-quality medications to patients, while remaining competitive in terms of cost in the industry.
  • July 2019: Pfizer Inc. and HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. agreed to combine Upjohn and Mylan to develop a new company. This development would help them to augment their business and deliver high-quality medicines to patients.

Request a Sample Copy of the Research Report: 

https://www.fortunebusinessinsights.com/enquiry/sample/antibiotics-market-104583

Drivers & Restraints-

Increasing Cases of Urinary Tract Infection to Drive Growth

The rising prevalence of multiple bacterial infections, such as skin infections, Urinary Tract Infection (UTI), tuberculosis, and respiratory infections worldwide is set to propel the antibiotics market growth in the near future. At the same time, the increasing burden of bacterial infections is anticipated to be the most common cause of death by 2050. As per the World Health Organization, around 50% of women have suffered from UTI at some point of their lives. However, the extended usage of broad-spectrum antibiotics can often cause antimicrobial resistance (AMR). It may hamper their demand.

To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit:

https://www.fortunebusinessinsights.com/antibiotics-market-104583

Segments-

PenicillinSegment Held 29.7% Share in 2020: Fortune Business Insights™

By drug class, this market is divided into penicillin, cephalosporin, aminoglycosides, tetracycline, macrolides, fluoroquinolones, sulfonamides, and others. Out of these, the penicillin segment generated 29.7% in terms of the antibiotics market share in 2020 and remained in the leading position. The surging usage of penicillin in numerous developed and emerging nations would boost growth. The European Centre for Disease Prevention and Control (ECDC), for instance, stated that penicillin was the most frequently used antibiotic, ranging from 33% (Germany) to 67% (Slovenia).

Quick Buy Antibiotics Market Report Research

https://www.fortunebusinessinsights.com/checkout-page/104583

Report Coverage

We follow an innovative research methodology that includes data triangulation on the basis of bottom-up and top-down approaches. We conduct extensive primary research to validate the projected market numbers. The data used to estimate the forecast for various segments at the country, regional, and global levels is collected through interviews with multiple reputed stakeholders. We also derive information from paid databases, industry journals, SEC filings, and other authentic resources. The report includes several details, such as drivers, opportunities, challenges, and dynamics of the market.

Regional Insights-

North America to Dominate Stoked by Development of New Antibiotics

Geographically, in 2020, North America procured USD 16.81 billion in terms of revenue. It is set to remain at the forefront throughout the forthcoming years on account of the introduction of various new drugs by prominent companies present in this region. Merck & Co., Inc., for instance, bagged the U.S. FDA approval for DIFICID (fidaxomicin). It will be used to treat Clostridioides Difficile-associated Diarrhea (CDAD) only in children belonging to the age group of six months and older. On the other hand, Europe is likely to remain in the second position because of the rapid development of the healthcare infrastructure in developed countries.

Competitive Landscape-

Key Players Focus on Expansion Strategies and Joint Ventures to Compete in the Market

The global market contains a large number of companies that are currently focusing on engaging in joint ventures or expanding their production capacities to gain a competitive edge. A few others are also striving to bag FDA approval for their newly developed drugs.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/antibiotics-market-104583

A list of renowned providers of antibiotics operating in the global market:

  • Pfizer Inc. (New York, U.S.)
  • Abbott (Illinois, U.S.)
  • GlaxoSmithKline plc. (London, U.K.)
  • Sanofi (Paris, France)
  • Novartis AG (Basel, Switzerland)
  • Bayer AG (Leverkusen, Germany)
  • Bristol-Myers Squibb Company (New York City, U.S.)
  • Merck & Co., Inc. (Kenilworth, U.S.)
  • Astellas Pharma Inc. (Tokyo, Japan)
  • Johnson &Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.) (New Brunswick, U.S.)

Related Reports:

Nasal Drug Delivery Market

Anti-obesity Drugs Market

Stretch Ceilings Market

Dedicated Outdoor Air System (DOAS) Market

Automotive Natural Gas Vehicle (NGV) Market

Tantalum Pentoxide Powder Market

Ethylene Octene Copolymer Market

Vehicle Multi-Angle Vision Market

Pet Insurance Market

Ventilator Market

Insulin Pump Market

Dental Equipment Market

Diabetes Devices Market